<DOC>
	<DOCNO>NCT01034995</DOCNO>
	<brief_summary>Primary Objective : - To evaluate efficacy three fix dos SSR125543 ( 20 mg daily , 50 mg daily , 100 mg daily ) compare placebo outpatient major depressive disorder , assess change baseline ( Day -1 ) Day 56 17-item Hamilton Depression Rating Scale ( HAM-D ) total score . Secondary Objectives : - To evaluate tolerability safety SSR125543 outpatient major depressive disorder - To evaluate plasma concentration SSR125543</brief_summary>
	<brief_title>A Trial Evaluating Efficacy Tolerability SSR125543 Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description>This duration trial 11 week .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Inclusion criterion : Patients diagnosis major depressive disorder , define Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision ( DSMIVTR ) criterion ( 296.3 ) confirm semistructured Mini International Neuropsychiatric Interview ( MINI ) . Exclusion criterion : Inpatient hospitalization screen Symptoms depression present &lt; 30 day &gt; 2 year Significant suicide risk Mild depression measure standard clinical research scale History failure respond antidepressant treatment Other psychiatric condition could obscure result study For woman childbearing potential , unwillingness use highly effective mean birth control The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>